Skip to main content
. Author manuscript; available in PMC: 2020 Jun 5.
Published in final edited form as: J Pediatr. 2013 Apr 24;163(3):686–691. doi: 10.1016/j.jpeds.2013.03.017

Figure 1.

Figure 1

Comparison of adverse event frequencies by metabolizer phenotype. Metabolizer phenotype classification was based on CYP2C19 haplotype. *P < .01 χ2 test for trend. L-EM, lansoprazole extensive metabolizer; L-PM, lansoprazole poor metabolizer.